Literature DB >> 21703192

Chemical composition of hepatic lipids mediates reperfusion injury of the macrosteatotic mouse liver through thromboxane A(2).

Ashraf Mohammad El-Badry1, Jae-Hwi Jang, Ahmed Elsherbiny, Claudio Contaldo, Yinghua Tian, Dimitri A Raptis, Endre Laczko, Wolfgang Moritz, Rolf Graf, Pierre-Alain Clavien.   

Abstract

BACKGROUND & AIMS: Chemical composition of hepatic lipids is an evolving player in steatotic liver ischemia/reperfusion (I/R) injury. Thromboxane A(2) (TXA(2)) is a vasoactive pro-inflammatory lipid mediator derived from arachidonic acid (AA), an omega-6 fatty acid (Ω-6 FA). Reduced tolerance of the macrosteatotic liver to I/R may be related to increased TXA(2) synthesis due to the predominance of Ω-6 FAs.
METHODS: TXA(2) levels elicited by I/R in ob/ob and wild type mice were assessed by ELISA. Ob/ob mice were fed Ω-3 FAs enriched diet to reduce hepatic synthesis of AA and TXA(2) or treated with selective TXA(2) receptor blocker before I/R.
RESULTS: I/R triggered significantly higher hepatic TXA(2) production in ob/ob than wild type animals. Compared with ob/ob mice on regular diet, Ω-3 FAs supplementation markedly reduced hepatic AA levels before ischemia and consistently blunted hepatic TXA(2) synthesis after reperfusion. Sinusoidal perfusion and hepatocellular damage were significantly ameliorated despite downregulation of heme oxygenase-1. Hepatic transcript and protein levels of IL-1β and neutrophil recruitment were significantly diminished after reperfusion. Moreover, TXA(2) receptor blockage conferred similar protection without modification of the histological pattern of steatosis. A stronger protection was achieved in the steatotic compared with lean animals.
CONCLUSIONS: Enhanced I/R injury in the macrosteatotic liver is explained, at least partially, by TXA(2) mediated microcirculatory failure rather than size-related mechanical compression of the sinusoids by lipid droplets. TXA(2) blockage may be a simple strategy to include steatotic organs and overcome the shortage of donor organs for liver transplantation.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703192     DOI: 10.1016/j.jhep.2011.04.019

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  5 in total

Review 1.  Ischemia–reperfusion injury in patients with fatty liver and the clinical impact of steatotic liver on hepatic surgery.

Authors:  Hirotaka Tashiro; Shintaro Kuroda; Yoshihiro Mikuriya; Hideki Ohdan
Journal:  Surg Today       Date:  2014-09       Impact factor: 2.549

Review 2.  Reactive oxygen and nitrogen species in steatotic hepatocytes: a molecular perspective on the pathophysiology of ischemia-reperfusion injury in the fatty liver.

Authors:  Megan J Reiniers; Rowan F van Golen; Thomas M van Gulik; Michal Heger
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

Review 3.  Strategies to rescue steatotic livers before transplantation in clinical and experimental studies.

Authors:  Qiang Liu; Maria-Louisa Izamis; Hongzhi Xu; Tim Berendsen; Martin Yarmush; Korkut Uygun
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

4.  "A randomized, double-blind study of the effects of omega-3 fatty acids (Omegaven) on outcome after major liver resection".

Authors:  Michael Linecker; Perparim Limani; Florin Botea; Irinel Popescu; Ruslan Alikhanov; Michail Efanov; Pavel Kim; Igor Khatkov; Dimitri Aristotele Raptis; Christoph Tschuor; Beatrice Beck-Schimmer; John Bonvini; Andrea Wirsching; Philipp Kron; Ksenija Slankamenac; Bostjan Humar; Rolf Graf; Henrik Petrowsky; Pierre-Alain Clavien
Journal:  BMC Gastroenterol       Date:  2015-08-14       Impact factor: 3.067

Review 5.  Computational Modeling in Liver Surgery.

Authors:  Bruno Christ; Uta Dahmen; Karl-Heinz Herrmann; Matthias König; Jürgen R Reichenbach; Tim Ricken; Jana Schleicher; Lars Ole Schwen; Sebastian Vlaic; Navina Waschinsky
Journal:  Front Physiol       Date:  2017-11-14       Impact factor: 4.566

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.